STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

ALLO Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 17.8M shares, representing 8.5% of Allogene Therapeutics, Inc. in this filing.

FiledOct 22, 2024
Ownership dateSep 30, 2024
Reported shares17.8M
Reported ownership8.5%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 17.8M
Shared voting power 17.8M
Sole dispositive power 17.8M
Shared dispositive power 17.8M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$2.80as of Oct 22, 2024
Latest tracked price$1.95as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0002012383
Accession
0002012383-24-001302
Form
Schedule 13G/A
Open SEC filing View ALLO ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →